Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant

NCT06197672 is registered in ClinicalTrials.gov with Huda Salman as lead sponsor.

NCT NCT06197672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06197672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant
Lead sponsor
Huda Salman
Phase
Phase 1
Overall status
Suspended
Start date
March 19, 2024
Completion date
December 31, 2042
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia